London, 11 November 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global Irritable Bowel Syndrome Market 2015-2019, which is expected to grow at a CAGR of 14.04 percent during the period 2014-2019.
Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the Centers for Disease Control and Prevention, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating.
“The expected launch of disorder-modifying drugs such as those targeting the root-cause of irritable bowel syndrome will help in the complete remission of patients,” says Faisal Ghaus, Vice President of TechNavio.
“These drugs, such as nerve growth factor binders, calcium channel blocker, and transient receptor potential vanilloid, are expected to be launched during the forecast period.”
Key Market Drivers
- Presence of Huge Unmet Needs
- Expected Launch of Pipeline Drugs
- Availability of Diagnostic Tools
- Increase in Disorder Incidence Rate
Key Market Trends
- Increase in Public Awareness
- Growing Focus on Developing Countries
- Expected Launch of Disorder-modifying Drugs
Key Market Vendors
- Actavis plc
- Astellas Pharma Inc.
- Nestlé SA
- Takeda Pharmaceutical Co. Ltd.
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
